Related Experiment Video

Updated: Aug 16, 2026

Isolation of Atrial Myocytes from Adult Mice
08:34

Isolation of Atrial Myocytes from Adult Mice

Published on: July 25, 2019

Current and emerging issues with B-type natriuretic peptide. Roundtable discussion

Marc A Silver1, Clive Rosendorff, Robert Berkowitz

  • 1Department of Medicine and the Heart Failure Institute, Advocate Christ Medical Center, Oak Lawn, IL 60453, USA. marc.silver@advocatehealth.com

Congestive Heart Failure (Greenwich, Conn.)
|August 18, 2005
PubMed

Insights

Primary care physicians discussed B-type natriuretic peptide (BNP) roles in cardiovascular diseases. The panel addressed key questions on heart failure and BNP utility.

Area of Science:

  • Cardiology
  • Biochemistry

Background:

  • A symposium for primary care physicians focused on B-type natriuretic peptide (BNP) in cardiovascular diseases.
  • BNP plays a crucial role in managing various heart conditions.

Purpose of the Study:

  • To address questions raised during a symposium on the clinical utility of BNP.
  • To clarify the role of BNP in cardiovascular disease management for primary care physicians.

Main Methods:

  • A panel discussion moderated by Dr. Marc A. Silver.
  • Expert insights from cardiologists including Dr. Clive Rosendorff, Dr. Robert Berkowitz, and Dr. W. Franklin Peacock IV.
  • Review of questions from symposium attendees regarding heart failure and BNP.

Main Results:

  • Discussion focused on the practical application of BNP testing in clinical settings.
  • Key questions regarding heart failure diagnosis and management using BNP were addressed.
  • Emphasis on BNP's importance in identifying and managing cardiovascular diseases.

Conclusions:

  • BNP is a valuable biomarker in cardiovascular disease, particularly in heart failure.
  • Further understanding and application of BNP testing can improve patient outcomes.
  • Continued dialogue is essential for optimizing BNP's role in primary care.

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...